GleamWall
中文EN

PBSV Pharma-Bio Serv, Inc.

Services-Management Consulting Services · OTC · SEC CIK 1304161 · Fiscal year ends 10/31

Financial factors as of 2026-07-31 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY3.3%
TTM net income YoY398.5%
TTM EPS YoY115.1%
Revenue 3-yr CAGR-19.3%
Net income 3-yr CAGR-45.2%

Margins

Gross margin32.3%
Operating margin-1.6%
Net margin2.7%
FCF margin-4.4%
EBITDA margin-1.0%

Returns

ROE2.2%
ROA2.0%
ROIC (approx.)-1.7%
Asset turnover0.76x

Leverage & solvency

Liabilities / assets8.7%
Debt / equity0.00x
Current ratio11.30x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-1.65x
Accruals ratio5.3%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-07-312026Q22026-04-302026Q12026-01-312025Q4*2025-10-312025Q32025-07-312025Q22025-04-302025Q12025-01-312024Q4*2024-10-31
Income statement
Revenue$2.34M$2.70M$2.29M$2.15M$1.96M$2.42M$2.47M$2.33M
Cost of revenue$1.64M$1.80M$1.57M$1.40M$1.39M$1.60M$1.70M$1.61M
Gross profit$691,734$902,041$722,374$748,935$574,262$818,726$768,109$726,570
SG&A expense$763,546$757,365$816,909$882,207$888,139$917,048$860,300$880,700
Operating income-$71,812$144,676-$94,535-$133,272-$313,877-$98,322-$92,191-$154,130
Pretax income-$11,098$239,353$36,490$4,254-$209,029$100,864$9,651-$14,849
Income tax$3,121$6,367$3,630$4,356-$4,779$5,511$1,115-$30,960
Net income-$14,219$232,986$32,860-$102-$204,250$95,353$8,536$16,111
EBITDA-$58,127$158,316-$79,739-$117,455-$298,133-$79,456-$82,752-$148,202
EPS (diluted)-0.000.010.00—-0.010.000.00—
Weighted avg. shares (diluted)22.91M22.91M22.91M—22.94M22.94M22.96M—
Balance sheet
Cash & equivalents$1.52M$1.79M$5.76M$3.38M$3.96M$2.09M$7.31M$6.77M
Short-term investments$7.06M$6.68M$4.80M$7.48M$6.77M$8.31M$5.13M$5.98M
Receivables$2.42M$2.72M$2.65M$2.36M$2.02M$2.68M$2.68M$2.51M
Current assets$11.24M$11.29M$13.32M$13.39M$13.16M$13.42M$15.53M$15.70M
PP&E, net$80,060$92,355$103,674$116,059$131,526$145,234$159,842$169,281
Total assets$11.44M$11.50M$13.55M$13.65M$13.59M$13.90M$16.08M$16.29M
Current liabilities$994,740$1.05M$3.31M$1.74M$1.66M$1.78M$3.42M$1.89M
Total liabilities$994,740$1.05M$3.31M$1.74M$1.66M$1.78M$4.08M$2.58M
Shareholders' equity$10.44M$10.45M$10.24M$11.91M$11.93M$12.12M$12.00M$13.72M
Shares outstanding22.90M22.90M22.90M22.91M22.92M22.93M22.96M22.96M
Cash flow statement
Operating cash flow$60,892-$365,311-$390,139$279,666$236,524-$301,590-$429,486$78,425
Capital expenditure$1,390$2,321$2,411$350$2,036$4,258$0$157,015
Free cash flow$59,502-$367,632-$392,550$279,316$234,488-$305,848-$429,486-$78,590
Investing cash flow-$326,303-$1.89M$2.77M-$856,665$1.63M-$3.23M$988,338$171,532
Financing cash flow$0-$1.72M-$1,681-$9,202-$5,004-$1.74M$0$0
Depreciation & amortization$13,685$13,640$14,796$15,817$15,744$18,866$9,439$5,928
Stock-based compensation$8,620$8,619$8,619$4,399$9,999$10,000$10,681$3,146
Dividends paid$0$1.72M—$0$0$1.72M—$0
Share buybacks$0$709$1,681$9,202$5,004$17,237$0$0

Free plan shows the latest 8 periods; Pro shows all 65 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.